Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12632528 | 0.91 | SPHK1 (0.31) | SPHK1SPHK2GLSPPARGPPARA | |
| SCHEMBL2052924 | 0.85 | PPARA (0.33) | SPHK1SPHK2GLSPPARGPPARA | |
| SCHEMBL2724637 | 0.84 | THRA (0.40) | SPHK1SPHK2THRATHRB | |
| SCHEMBL12610038 | 0.78 | PLK1 (0.31) | — | |
| SCHEMBL12610036 | 0.78 | GLS (0.33) | GLSPPARGPPARA | |
| SCHEMBL4137663 | 0.77 | THRA (0.36) | PPARGPPARATHRATHRB | |
| SCHEMBL4149000 | 0.77 | THRA (0.36) | PPARGPPARATHRATHRB | |
| SCHEMBL1603291 | 0.77 | CYP4A11 (0.39) | SPHK1GLSPPARA | |
| SCHEMBL15804691 | 0.77 | CYP4A11 (0.39) | SPHK1GLSPPARA | |
| SCHEMBL4143290 | 0.76 | THRA (0.35) | PPARGPPARATHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509938-A1 | FTY720 HALOGENATED DERIVATIVES | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070066-A1 | FTY720 HALOGENATED DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244071-A1 | FTY720 HALOGENATED DERIVATIVES | S1PR1, S1PR3, S1PR2 | LPL 2487/4885LIPG 1648/4885SPHK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.